Post-Viral Recovery

The Post-Viral Recovery stack is designed for individuals experiencing persistent fatigue, immune dysregulation, and inflammatory symptoms following viral infections — including but not limited to long COVID, post-EBV syndromes, and chronic fatigue syndrome with viral triggers. The protocol increases Thymosin Alpha-1 frequency to 3x weekly (from the standard 2x) to provide more aggressive immune reconstitution. Ta1''s ability to restore T-cell subset ratios (CD4/CD8 balance), enhance dendritic cell maturation, and promote interferon production makes it the cornerstone of post-viral immune recovery. Clinical data from COVID-19 treatment showed Ta1 reduced mortality and improved T-cell counts in critically ill patients. LL-37 is the only human cathelicidin — an antimicrobial peptide produced by neutrophils, macrophages, and epithelial cells as a first-line defense against pathogens. Beyond direct antimicrobial activity (it disrupts bacterial and viral membranes), LL-37 modulates immune cell recruitment, promotes wound healing, and importantly, helps resolve chronic inflammation by promoting macrophage phenotype switching from M1 (pro-inflammatory) to M2 (resolving/repair). In post-viral syndromes, persistent M1-dominant inflammation drives ongoing symptoms; LL-37 may help break this cycle. BPC-157 at twice-daily dosing provides systemic anti-inflammatory support and gut healing — critical because many post-viral syndromes involve gut barrier disruption and microbial translocation that perpetuate immune activation. Its modulation of the nitric oxide system and multiple growth factor pathways creates a tissue-repair environment throughout the body. The three-peptide combination addresses post-viral recovery comprehensively: Ta1 restores immune competence, LL-37 resolves chronic inflammation and provides antimicrobial coverage, and BPC-157 repairs tissue damage and restores gut barrier function. This is classified as intermediate due to the three-compound regimen and the clinical complexity of post-viral conditions.